Waleed H. Hassanein - Oct 15, 2024 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Role
President & CEO, Director
Signature
By: /s/ Stephen Gordon, Attorney-in-Fact
Stock symbol
TMDX
Transactions as of
Oct 15, 2024
Transactions value $
-$1,030,108
Form type
4
Date filed
10/17/2024, 04:30 PM
Previous filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMDX Common Stock Options Exercise $115K +8.63K +13.99% $13.28 70.3K Oct 15, 2024 Direct F1
transaction TMDX Common Stock Sale -$476K -3.61K -5.13% $131.91 66.7K Oct 15, 2024 Direct F1, F2
transaction TMDX Common Stock Sale -$467K -3.52K -5.28% $132.82 63.1K Oct 15, 2024 Direct F1, F3
transaction TMDX Common Stock Sale -$161K -1.2K -1.9% $134.23 61.9K Oct 15, 2024 Direct F1, F4
transaction TMDX Common Stock Sale -$40.5K -300 -0.48% $135.04 61.6K Oct 15, 2024 Direct F1, F5
holding TMDX Common Stock 469K Oct 15, 2024 By the Waleed H. Hassanein Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMDX Stock Option (Right to Buy) Options Exercise $0 -8.63K -8.22% $0.00 96.3K Oct 15, 2024 Common Stock 8.63K $13.28 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $131.29 to $132.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $132.34 to $133.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $133.57 to $134.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $134.63 to $135.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.